Trials / Completed
CompletedNCT03724825
Correlation of Serum Adropin to Testosterone and Adiponectin in Obese Men
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 82 (actual)
- Sponsor
- Aswan University Hospital · Academic / Other
- Sex
- Male
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
Obesity is associated with low testosterone in men and with dyslipidemia. Adropin hormone is negatively correlated with body mass index and is associated with dyslipidemia. correlation between adropin and testosterone will be evaluated.
Detailed description
Obesity, a worldwide epidemic is associated with multiple adverse health outcome as diabetes mellitus, hypertension and cardiovascular diseases caused mainly by dyslipidemia linked to obesity. Low testosterone levels in obese men were found associated with dyslipidemia. Adropin is a new metabolic hormone that was first isolated in liver and brain tissues, It was observed that mice fed on a high-fat diet (HFD) had a rapid increase in adropin expression compared to control values. In human also, adropin levels were negatively correlated with body mass index (BMI) and were associated with dyslipidemia. Adiponectin is a protein that is mainly produced by white adipose tissue and has an important role in lipid metabolism. Serum adiponectin concentrations were decreased in obese compared to normal weight men and significantly correlated with testosterone level.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | lipid profile: Total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL) and high density lipoprotein (HDL)) | blood samples will be collected after 10 hours fasting |
| DIAGNOSTIC_TEST | Total testosterone | blood samples will be collected after 10 hours fasting |
| DIAGNOSTIC_TEST | Adropin | blood samples will be collected after 10 hours fasting |
| DIAGNOSTIC_TEST | Adiponectin | blood samples will be collected after 10 hours fasting |
Timeline
- Start date
- 2018-12-01
- Primary completion
- 2019-11-29
- Completion
- 2020-01-07
- First posted
- 2018-10-30
- Last updated
- 2022-03-02
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT03724825. Inclusion in this directory is not an endorsement.